BriaCell Continues Clinical Operations Amidst COVID-19 Pandemic
March 26 2020 - 5:30AM
BriaCell Therapeutics Corp. (“BriaCell” or the “Company”)
(TSX-V:BCT) (OTCQB:BCTXF), a clinical-stage biotechnology
company specializing in targeted immunotherapy for advanced breast
cancer, announce that the Phase I/IIa clinical study of Bria-IMT™
with Incyte Corporation’s immune checkpoint inhibitor, INCMGA00012
is ongoing and recruiting patients amidst the COVID-19 pandemic. In
fact, BriaCell has enrolled a new patient in the study this week.
“We are determined to provide safe and effective
treatments for advanced breast cancer patients with no effective
treatment options. Our experts believe that our novel immunotherapy
may work additively or synergistically with checkpoint inhibitors
to boost the body's immune response to cancer cells and we are
firmly committed to continuing our scientific and clinical
advancements,” said Dr. Bill Williams, BriaCell’s President &
CEO.
“BriaCell’s clinical trial is ongoing throughout
the COVID-19 pandemic. We are confident that the participating
clinical sites in BriaCell’s clinical trial are fully compliant
with state-specific regulations, and will take every appropriate
measure to meet and exceed safety standards for their patients amid
the COVID-19 pandemic.”
BriaCell also has an abstract accepted for a
poster presentation at the American Association of Cancer Research
(AACR) meeting, which is typically held in April each year.
This year the COVID-19 pandemic has caused the meeting to be
postponed to August 2020. For more information go to
https://www.aacr.org/meeting/aacr-annual-meeting-2020/coronavirus-information/.
About AACR
The AACR was founded in Washington, D.C., May 7,
1907, by a group of 11 physicians and scientists intending “to
further the investigation and spread the knowledge of cancer.” To
prevent and cure cancer using research, education, communication,
collaboration, funding and advocacy has been the mission of AACR.
With its programs and services, AACR advances research in cancer
and related biomedical science by facilitating exchange of
knowledge and innovations among scientists and clinicians dedicated
to the fight against cancer, providing education and training in
oncology treatment and advancing cancer etiology, prevention, early
detection, diagnosis and treatment worldwide.
For more information on AACR, please visit:
https://www.aacr.org.
About BriaCell
BriaCell is an immuno-oncology focused
biotechnology company developing targeted and effective approaches
for the management of cancer.
For additional information on BriaCell, please
visit: https://briacell.com/.
Cautionary Note Regarding Forward-Looking
Information
Except for the statements of historical fact,
this news release contains "forward-looking information" within the
meaning of the applicable Canadian securities legislation (also
known as "forward-looking statements") which are subject to known
and unknown risks relevant to the Company in particular and to the
biotechnology and pharmaceutical industries in general,
uncertainties and other factors that may cause actual events to
differ materially from current expectation. These risks are more
fully described in the Company's public filings available at
www.sedar.com.
These forward-looking statements include, but
are not limited to, BriaCell’s plans, objectives, expectations and
intentions. Such forward-looking statements reflect BriaCell's
current beliefs and are based on information currently available to
management. Although the forward-looking statements contained in
this news release are based upon what BriaCell believes are
reasonable assumptions, there can be no assurance that actual
results will be consistent with these forward-looking
statements.
Readers are cautioned not to place undue
reliance on these forward-looking statements, which speak only as
of the date of this press release. The Company disclaims any
intention or obligation, except to the extent required by law, to
update or revise any forward-looking statements, whether as a
result of new information, future events or otherwise.
Neither TSX Venture Exchange nor its Regulation
Services Provider (as that term is defined in the policies of the
TSX Venture Exchange) accepts responsibility for the adequacy or
accuracy of this release.
Contact Information
For further information, please
contact:BriaCell Therapeutics Corp.:Farrah
DeanManager, Corporate DevelopmentEmail: farrah@BriaCell.com Phone:
1-888-485-6340
BriaCell Therapeutics (TSXV:BCT)
Historical Stock Chart
From Mar 2024 to Apr 2024
BriaCell Therapeutics (TSXV:BCT)
Historical Stock Chart
From Apr 2023 to Apr 2024